Filtered By:
Condition: Heart Attack
Management: WHO
Procedure: PET Scan
Countries: USA Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Dog Ownership Linked To 24% Lower Risk Of Dying Early, Research Shows
(CNN) — Need an excellent reason to add a dog to your life? How about living longer?
“Our analysis found having a dog is actually protective against dying of any cause,” said Mount Sinai endocrinologist Dr. Caroline Kramer, lead author of a new systematic review of nearly 70 years of global research published Tuesday in “Circulation,” a journal of the American Heart Association.
The review of the health benefits of man’s best friend analyzed research involving nearly 4 million people in the United States, Canada, Scandinavia, New Zealand, Australia and the United Kingdom.
“Dog owne...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 8, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Featured Health News Offbeat Syndicated CBSN Boston CNN Dogs Source Type: news
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news